ATE375153T1 - Verwendung von epoxydhydrolasekomplexe zur behandlung von hypertension - Google Patents
Verwendung von epoxydhydrolasekomplexe zur behandlung von hypertensionInfo
- Publication number
- ATE375153T1 ATE375153T1 AT00911767T AT00911767T ATE375153T1 AT E375153 T1 ATE375153 T1 AT E375153T1 AT 00911767 T AT00911767 T AT 00911767T AT 00911767 T AT00911767 T AT 00911767T AT E375153 T1 ATE375153 T1 AT E375153T1
- Authority
- AT
- Austria
- Prior art keywords
- sulfur
- oxygen
- hydrogen
- nitrogen
- epoxydhydrolase
- Prior art date
Links
- 206010020772 Hypertension Diseases 0.000 title 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 3
- 229910052739 hydrogen Inorganic materials 0.000 abstract 3
- 239000001257 hydrogen Substances 0.000 abstract 3
- 229910052757 nitrogen Inorganic materials 0.000 abstract 3
- 229910052760 oxygen Inorganic materials 0.000 abstract 3
- 239000001301 oxygen Substances 0.000 abstract 3
- 229910052717 sulfur Inorganic materials 0.000 abstract 3
- 239000011593 sulfur Substances 0.000 abstract 3
- 102000005486 Epoxide hydrolase Human genes 0.000 abstract 2
- 108020002908 Epoxide hydrolase Proteins 0.000 abstract 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 2
- 239000003112 inhibitor Substances 0.000 abstract 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 102100025357 Lipid-phosphate phosphatase Human genes 0.000 abstract 1
- 108030006933 Soluble epoxide hydrolases Proteins 0.000 abstract 1
- 125000002252 acyl group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- -1 cycloakyl Chemical group 0.000 abstract 1
- 239000007857 degradation product Substances 0.000 abstract 1
- 125000001188 haloalkyl group Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 150000002431 hydrogen Chemical class 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 239000002207 metabolite Substances 0.000 abstract 1
- 238000000926 separation method Methods 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Molecular Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/252,148 US6150415A (en) | 1996-08-13 | 1999-02-18 | Epoxide hydrolase complexes and methods therewith |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE375153T1 true ATE375153T1 (de) | 2007-10-15 |
Family
ID=22954799
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT00911767T ATE375153T1 (de) | 1999-02-18 | 2000-02-10 | Verwendung von epoxydhydrolasekomplexe zur behandlung von hypertension |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US6150415A (de) |
| EP (2) | EP1154764B1 (de) |
| JP (1) | JP2002540767A (de) |
| AT (1) | ATE375153T1 (de) |
| AU (1) | AU3360800A (de) |
| CA (1) | CA2362331C (de) |
| DE (1) | DE60036690T2 (de) |
| DK (1) | DK1154764T3 (de) |
| ES (1) | ES2291196T3 (de) |
| WO (1) | WO2000048593A1 (de) |
Families Citing this family (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8815951B2 (en) * | 1996-08-13 | 2014-08-26 | The Regents Of The University Of California | Inhibitors of epoxide hydrolases for the treatment of inflammation |
| US6150415A (en) * | 1996-08-13 | 2000-11-21 | The Regents Of The University Of California | Epoxide hydrolase complexes and methods therewith |
| US7517880B2 (en) | 1997-12-22 | 2009-04-14 | Bayer Pharmaceuticals Corporation | Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas |
| US7928239B2 (en) | 1999-01-13 | 2011-04-19 | Bayer Healthcare Llc | Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas |
| US7351834B1 (en) | 1999-01-13 | 2008-04-01 | Bayer Pharmaceuticals Corporation | ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| WO2000041698A1 (en) | 1999-01-13 | 2000-07-20 | Bayer Corporation | φ-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS |
| WO2000042012A1 (en) * | 1999-01-13 | 2000-07-20 | Bayer Corporation | φ-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS |
| US6831099B1 (en) * | 1999-05-12 | 2004-12-14 | Yale University | Enzyme inhibition |
| ES2165768B1 (es) | 1999-07-14 | 2003-04-01 | Almirall Prodesfarma Sa | Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen. |
| US6562563B1 (en) | 1999-11-03 | 2003-05-13 | Mitokor | Compositions and mehtods for determining interactions of mitochondrial components, and for identifying agents that alter such interactions |
| US7235576B1 (en) | 2001-01-12 | 2007-06-26 | Bayer Pharmaceuticals Corporation | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| WO2002082082A2 (en) * | 2001-04-09 | 2002-10-17 | Boehringer Ingelheim Pharmaceuticals, Inc. | Fluorescence polarization assay |
| US7371763B2 (en) | 2001-04-20 | 2008-05-13 | Bayer Pharmaceuticals Corporation | Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas |
| US6756210B2 (en) * | 2001-05-29 | 2004-06-29 | The Regents Of The University Of California | Linoleic acid diol and glucuronide conjugate levels as diagnostic markers of disorders of abnormal regulation of cytochrome P450 metabolism of unsaturated fatty acids |
| EP1578987A2 (de) * | 2001-08-03 | 2005-09-28 | Diversa Corporation | Epoxidhydrolasen, diese codierende nukleinsäuren sowie verfahren zu deren herstellung und verwendung |
| US6943001B2 (en) * | 2001-08-03 | 2005-09-13 | Diversa Corporation | Epoxide hydrolases, nucleic acids encoding them and methods for making and using them |
| US20030139469A1 (en) * | 2002-01-23 | 2003-07-24 | The Regents Of The University Of California | Use of inhibitors of soluble epoxide hydrolase to inhibit vascular smooth muscle cell proliferation |
| EP2324825A1 (de) | 2002-02-11 | 2011-05-25 | Bayer Healthcare LLC | Arylharnstoffe mit Angiogenese hemmender Aktivität |
| US20030216396A1 (en) | 2002-02-11 | 2003-11-20 | Bayer Corporation | Pyridine, quinoline, and isoquinoline N-oxides as kinase inhibitors |
| DK1580188T3 (da) | 2002-02-11 | 2012-02-06 | Bayer Healthcare Llc | Forbindelser af arylurea som kinaseinhibitorer |
| GB0214342D0 (en) * | 2002-06-21 | 2002-07-31 | Givaudan Sa | Insect repellents |
| CN100408556C (zh) | 2002-10-07 | 2008-08-06 | 加利福尼亚大学董事会 | 通过阻断花生四烯酰乙醇酰胺的水解调节焦虑 |
| UY28213A1 (es) | 2003-02-28 | 2004-09-30 | Bayer Pharmaceuticals Corp | Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos. |
| WO2005089380A2 (en) | 2004-03-16 | 2005-09-29 | The Regents Of The University Of California | Reducing nephropathy with inhibitors of soluble epoxide hydrolase and epoxyeicosanoids |
| EP1608319A4 (de) * | 2003-04-03 | 2007-02-28 | Univ California | Verbesserte hemmer für lösliche epoxidhydrolase |
| US20050164951A1 (en) * | 2003-04-03 | 2005-07-28 | The Regents Of The University Of California | Inhibitors for the soluble epoxide hydrolase |
| DK1626714T3 (da) | 2003-05-20 | 2007-10-15 | Bayer Pharmaceuticals Corp | Dirarylurinstoffer mod sygdomme medieret af PDGFR |
| CN1856469B (zh) | 2003-07-23 | 2013-03-06 | 拜耳医药保健有限责任公司 | 用于治疗和预防疾病和疾病症状的氟代ω-羧芳基二苯基脲 |
| ES2257152B1 (es) * | 2004-05-31 | 2007-07-01 | Laboratorios Almirall S.A. | Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos. |
| CA2584342C (en) * | 2004-10-20 | 2013-04-30 | The Regents Of The University Of California | Improved inhibitors for the soluble epoxide hydrolase |
| JP2008540424A (ja) * | 2005-05-06 | 2008-11-20 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ｓＥＨインヒビターとしてのアシルヒドラゾンの使用方法 |
| WO2006121719A2 (en) * | 2005-05-06 | 2006-11-16 | Boehringer Ingelheim International, Gmbh | Soluble epoxide hydrolase inhibitors and methods of using same |
| ATE555656T1 (de) * | 2005-08-19 | 2012-05-15 | Univ California | Verwendung von seh-hemmern als analgetika |
| EP1934182A1 (de) * | 2005-10-07 | 2008-06-25 | Boehringer Ingelheim International Gmbh | Als lösliche epoxidhydrolaseinhibitoren geeignete n-substituierte pyridinon- oder pyrimidinonverbindungen |
| JP5436860B2 (ja) | 2005-11-09 | 2014-03-05 | オニキス セラピューティクス， インク． | 酵素阻害のための化合物 |
| JP2009523134A (ja) * | 2006-01-13 | 2009-06-18 | マクギル ユニバーシティー | 抗うつ作用ならびに睡眠誘発性を有する新規なメラトニンリガンド |
| WO2007106705A1 (en) * | 2006-03-10 | 2007-09-20 | Boehringer Ingelheim International Gmbh | Soluble epoxide hydrolase inhibitors and methods of using same |
| AR059826A1 (es) | 2006-03-13 | 2008-04-30 | Univ California | Inhibidores de urea conformacionalmente restringidos de epoxido hidrolasa soluble |
| MY183014A (en) | 2006-06-19 | 2021-02-05 | Onyx Therapeutics Inc | Compounds for enzyme inhibition |
| WO2008073130A1 (en) * | 2006-12-15 | 2008-06-19 | Regents Of The University Of California | Use of cis-epoxyeicosatrienoic acids and inhibitors of soluble epoxide hydrolase to treat conditions mediated by pbr, cb2, and nk2 receptors |
| WO2008074678A1 (en) * | 2006-12-18 | 2008-06-26 | F. Hoffmann-La Roche Ag | Novel use of inhibitors of soluble epoxide hydrolase |
| EP2178534A4 (de) * | 2007-07-17 | 2011-03-30 | Merck Sharp & Dohme | Lösliche epoxidhydrolasehemmer, zusammensetzungen mit solchen verbindungen und behandlungsverfahren damit |
| EP2187746A4 (de) | 2007-08-06 | 2011-01-19 | Univ California | Herstellung von neuen 1,3-substituierten harnstoffen als hemmer der löslichen epoxidhydrolase |
| KR20150131405A (ko) * | 2007-10-04 | 2015-11-24 | 오닉스 세라퓨틱스, 인크. | 결정형 펩티드 에폭시 케톤 프로테아제 저해제 및 아미노산 케토-에폭시드의 합성 |
| EP2259680A4 (de) * | 2008-03-04 | 2012-01-25 | Merck Sharp & Dohme | Lösliche epoxidhydrolasehemmer, zusammensetzungen mit derartigen verbindungen und behandlungsverfahren damit |
| EP2100599A1 (de) | 2008-03-13 | 2009-09-16 | Laboratorios Almirall, S.A. | Inhalationszusammensetzung enthaltend Aclidinium zur Behandlung von Asthma sowie chronisch-obstruktiver Lungenerkrankung |
| EP2100598A1 (de) | 2008-03-13 | 2009-09-16 | Laboratorios Almirall, S.A. | Inhalationszusammensetzung enthaltend Aclidinium zur Behandlung von Asthma sowie chronisch-obstruktiver Lungenerkrankung |
| JP5675629B2 (ja) | 2008-10-21 | 2015-02-25 | オニキス セラピューティクス， インク．Ｏｎｙｘ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． | ペプチドエポキシケトンを用いた併用療法 |
| WO2010096722A1 (en) | 2009-02-20 | 2010-08-26 | Takeda Pharmaceutical Company Limited | 3-oxo-2, 3-dihydro- [1,2, 4] triazolo [4, 3-a]pyridines as soluble epoxide hydrolase (seh) inhibitors |
| AR075899A1 (es) | 2009-03-20 | 2011-05-04 | Onyx Therapeutics Inc | Tripeptidos epoxicetonas cristalinos inhibidores de proteasa |
| WO2011060179A1 (en) | 2009-11-13 | 2011-05-19 | Onyx Therapeutics, Inc | Use of peptide epoxyketones for metastasis suppression |
| US9296693B2 (en) | 2010-01-29 | 2016-03-29 | The Regents Of The University Of California | Acyl piperidine inhibitors of soluble epoxide hydrolase |
| CA2791651C (en) | 2010-03-01 | 2019-08-20 | Onyx Therapeutics, Inc. | Compounds for immunoproteasome inhibition |
| AU2011245630B2 (en) | 2010-04-07 | 2014-07-03 | Onyx Therapeutics, Inc. | Crystalline peptide epoxyketone immunoproteasome inhibitor |
| EP2389922A1 (de) | 2010-05-25 | 2011-11-30 | Symrise AG | Cyclohexylcarbamatverbindungen als Anti-ageing-Wirkstoffe |
| EP2675274B1 (de) | 2011-02-14 | 2017-05-03 | The Regents of The University of California | Sorafenib-derivate als seh-hemmer |
| EP2510928A1 (de) | 2011-04-15 | 2012-10-17 | Almirall, S.A. | Aclidinium zur Verbesserung der Schlafqualität bei atemwegserkrankten Patienten |
| US9034903B2 (en) | 2012-02-01 | 2015-05-19 | The Regents Of The University Of California | Acyl piperidine inhibitors of soluble epoxide hydrolase |
| US10383835B2 (en) | 2012-03-14 | 2019-08-20 | The Regents Of The University Of California | Treatment of inflammatory disorders in non-human mammals |
| US9309283B2 (en) | 2012-07-09 | 2016-04-12 | Onyx Therapeutics, Inc. | Prodrugs of peptide epoxy ketone protease inhibitors |
| WO2016133788A1 (en) | 2015-02-20 | 2016-08-25 | The Regents Of The University Of California | Methods of inhibiting pain |
| US20200317813A1 (en) | 2016-05-25 | 2020-10-08 | Johann Wolfgang Goethe-Universitat Frankfurt Am Main | Treatment and diagnosis of non-proliferative diabetic retinopathy |
| US20210378995A1 (en) | 2018-10-10 | 2021-12-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and topical pharmaceutical compositions for the treatment of skin microvascular dysfunction |
| JP7498708B2 (ja) | 2018-11-09 | 2024-06-12 | ギンゴー バイオワークス， インコーポレイテッド | モグロシドの生合成 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1056290A (en) * | 1963-05-06 | 1967-01-25 | Du Pont | Dicycloalkyl ureas |
| CA2017383A1 (en) * | 1989-06-08 | 1990-12-08 | Raymond R. Martodam | Use of vanilloids for the treatment of respiratory diseases or disorders |
| CA2036770C (en) * | 1990-02-26 | 2003-09-09 | Jeffrey P. Whitten | Inhibitors of nitric oxide biosynthesis |
| US5445956A (en) * | 1993-08-13 | 1995-08-29 | The Regents Of The University Of California | Recombinant soluble epoxide hydrolase |
| US5599984A (en) * | 1994-01-21 | 1997-02-04 | The Picower Institute For Medical Research | Guanylhydrazones and their use to treat inflammatory conditions |
| JP2909620B2 (ja) * | 1995-03-07 | 1999-06-23 | 参天製薬株式会社 | Ｎ，ｎ−ジアルキルアミノフェニル基を有する新規アミノ酸誘導体 |
| US6150415A (en) * | 1996-08-13 | 2000-11-21 | The Regents Of The University Of California | Epoxide hydrolase complexes and methods therewith |
| US5955496A (en) * | 1996-08-13 | 1999-09-21 | The Regents Of The University Of California | Dihydroxy-oxy-eicosadienoates |
-
1999
- 1999-02-18 US US09/252,148 patent/US6150415A/en not_active Expired - Lifetime
-
2000
- 2000-02-10 EP EP00911767A patent/EP1154764B1/de not_active Expired - Lifetime
- 2000-02-10 AT AT00911767T patent/ATE375153T1/de active
- 2000-02-10 WO PCT/US2000/003495 patent/WO2000048593A1/en not_active Ceased
- 2000-02-10 EP EP07014966A patent/EP1844767B1/de not_active Expired - Lifetime
- 2000-02-10 DK DK00911767T patent/DK1154764T3/da active
- 2000-02-10 JP JP2000599385A patent/JP2002540767A/ja active Pending
- 2000-02-10 AU AU33608/00A patent/AU3360800A/en not_active Abandoned
- 2000-02-10 ES ES00911767T patent/ES2291196T3/es not_active Expired - Lifetime
- 2000-02-10 CA CA2362331A patent/CA2362331C/en not_active Expired - Fee Related
- 2000-02-10 DE DE60036690T patent/DE60036690T2/de not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| EP1844767A3 (de) | 2010-01-13 |
| JP2002540767A (ja) | 2002-12-03 |
| CA2362331A1 (en) | 2000-08-24 |
| WO2000048593A1 (en) | 2000-08-24 |
| DK1154764T3 (da) | 2008-02-04 |
| EP1154764A1 (de) | 2001-11-21 |
| ES2291196T3 (es) | 2008-03-01 |
| EP1154764A4 (de) | 2005-02-16 |
| EP1844767A2 (de) | 2007-10-17 |
| DE60036690D1 (de) | 2007-11-22 |
| US6150415A (en) | 2000-11-21 |
| EP1154764B1 (de) | 2007-10-10 |
| EP1844767B1 (de) | 2012-08-29 |
| AU3360800A (en) | 2000-09-04 |
| CA2362331C (en) | 2010-04-20 |
| DE60036690T2 (de) | 2008-07-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE375153T1 (de) | Verwendung von epoxydhydrolasekomplexe zur behandlung von hypertension | |
| NZ505968A (en) | Sulfonylamino derivatives which inhibit matrix- degrading metallproteinases | |
| ATE202702T1 (de) | Verwendung von oestrogenagonisten und - antagonisten zur herstellung eines medikaments zur behandlung von atherosklerose, unabhängig von lipidsenkung | |
| TR200402157T2 (tr) | Heteroaril süksinamidler ve metalloproteinaz inhibitörü olarak kullanımları | |
| RU95105988A (ru) | Производные эфиров о-бензилоксимов, способ их получения и пестицидная композиция на их основе | |
| DE69332792T2 (de) | 4,1-Benzoxazepinderivate als Squalen-Synthetase Inhibitoren und ihre Verwendung zur Behandlung von Hypercholesterämie und als Fungizide | |
| NO174549C (no) | Analogifremgangsmåte for fremstilling av terapeutisk aktive, asymmetrisk substituerte, heterocykliske forbindelser | |
| DE68906183D1 (de) | 2'-desoxy-5-fluoruridinderivate. | |
| BR9508901A (pt) | Di-hidrobenzofurano e composto relacionados utilizáveis como agentes antiflamatórios | |
| PH19684A (en) | Biologically acitve heterocyclic compounds | |
| ATE251624T1 (de) | Granulatimide-derivate zur behandlung von krebs | |
| DE69319764D1 (de) | Verfahren zur Herstellung von Beta-Lactamderivaten und Zwischenprodukt für ihre Synthese | |
| DK1000034T3 (da) | Substituerede 6-alkylphenanthridiner | |
| PL336857A1 (en) | Heterocyclic compounds, method of obtaining them and pharmaceutic composition containing such compounds | |
| DE69910568D1 (de) | Furopyridinderivate und ihre therapeutische verwendung | |
| BR9813923A (pt) | N n - bis(sulfonil) hidrazinas úteis como agentes antineoplásicos | |
| MY121785A (en) | Hydroxamic acid derivatives as inhibitors of the production of soluble cd23 | |
| BR9707321A (pt) | Dihidrobenzofurano e compostor correlatos úteis como agentes antinflamatórios | |
| ATE147938T1 (de) | Inhibitoren der dihydrofolatreduktase von pneumocystis carinii | |
| DE69320730D1 (de) | Alkylendiaminderivate | |
| ATE255561T1 (de) | Verfahren und zusammensetzungen zur behandlung von leukämie | |
| ATE120741T1 (de) | N-hydroxy-dibenz(b,e>oxepin-alkylamine und - alkanoische säureamide, verwandte heterocyclische analoge, verfahren zu ihrer herstellung und ihre verwendung zur herstellung von medikamenten. | |
| ATE253050T1 (de) | Aminderivate von oxo- und hydroxy- substituierten kohlenwasserstoffen | |
| BR0110328A (pt) | Compostos heterocìclicos com atividade antiinflamatória | |
| YU47797B (sr) | Heterociklična jedinjenja koja sadrže azot i sumpor i postupci za njihovo dobijanje |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1154764 Country of ref document: EP |